Search Results - "Rupnow, M F"

The risks and costs of multiple-generic substitution of topiramate by DUH, M. S, PARADIS, P. E, LATREMOUILLE-VIAU, D, GREENBERG, P. E, LEE, S. P, DURKIN, M. B, WAN, G. J, RUPNOW, M. F. T, LELORIER, J

“…To investigate clinical and economic consequences following generic substitution of one vs multiple generics of topiramate (Topamax; Ortho-McNeil Neurologics,…”
Get full text

PDB16 - Real-world treatment patterns of antihyperglycemic agents among patients with type 2 diabetes melltus (T2dm) Initiated on canagliflozin by Chow, W, Buysman, EK, Rupnow, MF, Henk, HJ

Get full text

Real-world treatment patterns of antihyperglycemic agents among patients with type 2 diabetes melltus (T2dm) Initiated on canagliflozin by Chow, W, Buysman, EK, Rupnow, MF, Henk, HJ

Get full text

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version by Cole, J C, Lin, P, Rupnow, M F T

“…To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no…”
Get more information

Quantifying the population impact of a prophylactic Helicobacter pylori vaccine by Rupnow, Marcia F.T., Shachter, Ross D., Owens, Douglas K., Parsonnet, Julie

“…Background: Helicobacter pylori vaccines, which have been suggested as promising interventions to control infection, are under development. We sought to…”
Get full text

A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States by Rupnow, M F, Shachter, R D, Owens, D K, Parsonnet, J

“…To assess the benefits of intervention programs against Helicobacter pylori infection, we estimated the baseline curves of its incidence and prevalence. We…”
Get full text

Helicobacter pylori Vaccine Development and Use: A Cost-Effectiveness Analysis Using the Institute of Medicine Methodology by Rupnow, Marcia F.T., Owens, Douglas K., Shachter, Ross, Parsonnet, Julie

“…Background. Prophylactic vaccination has been suggested as a better strategy than antibiotics to control Helicobacter pylori infection. We evaluated the…”
Get full text

PHP101 DIFFERENCES IN CLINICIAN REPORTED EASE OF USE BETWEEN 2 HEMOSTASIS TREATMENT METHODS: RESULTS FROM A RANDOMIZED CONTROLLED STUDY by Rupnow, MF, McCormack, J, Vernon, M, Batiller, J, Hammond, J

Get full text

PHP111 IMPACT OF BLEEDING-RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS ON HOSPITAL LENGTH OF STAY AND COSTS IN INPATIENT SURGICAL PATIENTS by Stokes, M, Ye, X, Mercaldi, K, Reynolds, MW, Rupnow, MF, Hammond, J

Get full text

PHP119 ROLE OF QUALITY IMPROVEMENT FOR MANAGEMENT OF SURGICAL BLEED COMPLICATIONS (SBCS) by Mohandas, A, Foley, K, Rupnow, MF, Nash, D, Doria, C

Get full text

PMH37 TREATMENT PERSISTENCE AND COMPLIANCE WITH GALANTAMINE ER by Yeaw, J, Crivera, C, Rupnow, MF, Ollendorf, D

Get full text

PHP98 COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS by Stokes, ME, Shah, M, Williams, K, Reynolds, MW, Rupnow, MF, Hammond, J

Get full text

PND19 THE ECONOMIC IMPACT OF ACUTE MEDICATION OVERUSE AMONG PATIENTS WITH MIGRAINE OR HEADACHE: A MANAGED CARE PERSPECTIVE by Pesa, JA, Thayer, S, Rupnow, MF, Biondi, D, Yaldo, A

Get full text

PND7 RELATION OF HEADACHE FREQUENCY TO HEALTH CARE UTILIZATION, WORK PRODUCTIVITY, AND TOTAL COSTS: RESULTS FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION (AMPP) STUDY by Munakata, J, Serrano, D, Klingman, D, Hazard, E, Rupnow, MF, Tierce, J, Reed, M, Stewart, WF, Lipton, RB

Get full text

PMH51 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE by Locklear, J, Edwards, N, Rupnow, MF, Diamond, R

Get full text

PND11 LIFETIME CLINICAL AND ECONOMIC CONSEQUENCES OF CHANGES IN BODY WEIGHT ASSOCIATED WITH MIGRAINE HEADACHE PROPHYLAXIS WITH TOPIRAMATE VERSUS AMITRIPTYLINE by Vera-Llonch, M, Rupnow, MF, Gagne, JJ, Siu, T, Oster, G

Get full text

PND30 COMORBIDITIES, ECONOMIC AND HUMANISTIC FACTORS ASSOCIATED WITH MIGRAINE:A PROPENSITY SCORE ANALYSIS OF NATIONAL SURVEY DATA by Gagne, JJ, Bolge, SC, Mills, DL, Rupnow, MF

Get full text

PND4 RESOURCE UTILIZATION PATTERNS WITH TOPIRAMATE FOR MIGRAINE PREVENTION IN THE MANAGED CARE SETTING by Yaldo, AZ, Wertz, D, Rupnow, MF, Quimbo, R

Get full text

PND46 THE RISKS OF MULTIPLE GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS: THE CASE OFTOPIRAMATE by Lelorier, J, Duh, MS, Paradis, PE, Latremouille-Viau, D, Sheehy, O, Greenberg, P, Lee, SP, Rupnow, MF

Get full text

PND16 ASSOCIATION OF LONG-TERM MIGRAINE PREVENTIVE MEDICATION USE AND RESOURCE UTILIZATION/PRODUCTIVITY LOSS: RESULTS FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION (AMPP) STUDY by Munakata, J, Hazard, E, Tierce, JC, Rupnow, MF, Serrano, D, Reed, M, Lipton, R

Get full text